Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 832 across all filing types
Latest filing 2026-05-12 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 90% confidence The document is titled as a press release reporting first quarter 2026 financial results and a business update. It contains summarized revenue figures, cash position, net debt, financing events, post-period updates, and highlights (e.g., board composition changes, product pipeline developments). It does not present full audited financial statements or a comprehensive interim report format, but rather a concise announcement of quarterly results and key business developments. This aligns with an Earnings Release (initial announcement of quarterly/periodical financial results). Q1 2026
2026-05-12 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 90% confidence The document is a press release titled “Adocia publie ses résultats financiers du premier trimestre 2026,” it provides headline Q1 financial results (revenues, cash position, debt) in tabular form, commentary from management, and operational updates. It is not a full interim report (with complete financial statements and notes) but rather an initial earnings announcement for the quarter. Thus it fits the Earnings Release category. Q1 2026
2026-05-12 French
Modalités de mise à disposition des documents préparatoires à l'AG
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a French press release from Adocia providing shareholders with formal notice of the Annual General Meeting (AGM) date, agenda, resolutions, and voting procedures—including proxy and remote voting instructions. It serves as the company’s proxy solicitation and information statement for the upcoming AGM, specifying how shareholders can obtain meeting materials, vote, or grant proxies. This aligns with the definition of category “Proxy Solicitation & Information Statement (PSI).”
2026-05-11 French
Terms of availability of the preparatory documents for the GM
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a press release announcing the convening of the Annual General Meeting, providing the date, agenda, proposed resolutions, and instructions for voting and proxy submission. It is a solicitation of proxies and informs shareholders how to participate and vote. This matches the definition of a Proxy Solicitation & Information Statement, which covers materials sent to shareholders to request votes for meetings.
2026-05-11 English
Inside Information / Other news releases
Regulatory Filings
2026-05-07 English
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.